Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
$6.90
+1.2%
$6.66
$4.66
$7.86
$113.33M0.658,895 shs1,386 shs
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
$1.52
+9.1%
$1.25
$0.77
$2.63
$125.30M1.04308,989 shs368,415 shs
Cesca Therapeutics Inc stock logo
KOOL
Cesca Therapeutics
$11.89
+0.9%
$2.78
$2.10
$7.00
$28.72M1.07112,188 shs386 shs
ThermoGenesis Holdings, Inc. stock logo
THMO
ThermoGenesis
$0.00
$0.00
$0.60
$1K1.175,900 shsN/A
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
+1.17%+1.47%+4.07%+24.55%+689,999,900.00%
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
+9.06%+3.13%+15.73%+87.16%-21.04%
Cesca Therapeutics Inc stock logo
KOOL
Cesca Therapeutics
+0.47%+1.77%+5.67%+19.47%+12.32%
ThermoGenesis Holdings, Inc. stock logo
THMO
ThermoGenesis
0.00%0.00%0.00%-66.67%-99.93%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
N/AN/AN/AN/AN/AN/AN/AN/A
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
2.0824 of 5 stars
3.73.00.00.01.10.00.6
Cesca Therapeutics Inc stock logo
KOOL
Cesca Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
ThermoGenesis Holdings, Inc. stock logo
THMO
ThermoGenesis
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
3.00
Buy$13.6798.07% Upside
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
3.33
Buy$8.00427.70% Upside
Cesca Therapeutics Inc stock logo
KOOL
Cesca Therapeutics
0.00
N/AN/AN/A
ThermoGenesis Holdings, Inc. stock logo
THMO
ThermoGenesis
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest KOOL, THMO, CRDL, and BHST Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/2/2025
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$9.00
5/5/2025
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$15.00
4/16/2025
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
4/8/2025
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$14.00 ➝ $14.00
4/7/2025
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
$27.70M4.09N/AN/A$0.08 per share86.25
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
N/AN/AN/AN/A$0.22 per shareN/A
Cesca Therapeutics Inc stock logo
KOOL
Cesca Therapeutics
$9.67M2.97N/AN/A$3.11 per share3.82
ThermoGenesis Holdings, Inc. stock logo
THMO
ThermoGenesis
$9.61M0.00N/AN/A($0.99) per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
-$12.91M-$0.50N/AN/AN/A-31.30%-307.04%-33.21%8/14/2025 (Estimated)
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
-$26.77M-$0.34N/AN/AN/AN/A-209.63%-141.09%7/14/2025 (Estimated)
Cesca Therapeutics Inc stock logo
KOOL
Cesca Therapeutics
-$39.72M-$3.60N/A1,188.88N/A-98.84%-77.30%-37.75%N/A
ThermoGenesis Holdings, Inc. stock logo
THMO
ThermoGenesis
-$17.98M-$5.14N/AN/AN/AN/AN/AN/AN/A

Latest KOOL, THMO, CRDL, and BHST Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
-$0.15-$0.13+$0.02-$0.13$8.93 million$7.64 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
N/AN/AN/AN/AN/A
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
N/AN/AN/AN/AN/A
Cesca Therapeutics Inc stock logo
KOOL
Cesca Therapeutics
N/A0.50%N/AN/AN/A
ThermoGenesis Holdings, Inc. stock logo
THMO
ThermoGenesis
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
N/A
0.51
0.30
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
0.01
3.26
3.26
Cesca Therapeutics Inc stock logo
KOOL
Cesca Therapeutics
0.50
1.52
0.91
ThermoGenesis Holdings, Inc. stock logo
THMO
ThermoGenesis
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
N/A
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
12.49%
Cesca Therapeutics Inc stock logo
KOOL
Cesca Therapeutics
3.11%
ThermoGenesis Holdings, Inc. stock logo
THMO
ThermoGenesis
5.78%

Insider Ownership

CompanyInsider Ownership
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
N/A
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
5.25%
Cesca Therapeutics Inc stock logo
KOOL
Cesca Therapeutics
68.90%
ThermoGenesis Holdings, Inc. stock logo
THMO
ThermoGenesis
78.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
N/A16.43 millionN/AN/A
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
2082.65 million78.31 millionNot Optionable
Cesca Therapeutics Inc stock logo
KOOL
Cesca Therapeutics
532.42 millionN/ANot Optionable
ThermoGenesis Holdings, Inc. stock logo
THMO
ThermoGenesis
407.95 million1.75 millionNot Optionable

Recent News About These Companies

North American Morning Briefing: Stock Futures, -2-
Why Is ThermoGenesis (THMO) Stock Down 37% Today?
ThermoGenesis Holdings, Inc.
ThermoGenesis Holdings Recent Insider Activity
ThermoGenesis Q3 Earnings Preview
Here's what Wall Street expects from ThermoGenesis's earnings report
ThermoGenesis Holdings Inc THMO
ThermoGenesis Holdings Earnings Preview

New MarketBeat Followers Over Time

Media Sentiment Over Time

BioHarvest Sciences stock logo

BioHarvest Sciences NASDAQ:BHST

$6.90 +0.08 (+1.17%)
As of 07/3/2025 12:59 PM Eastern

BioHarvest Sciences Inc. is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications. BioHarvest Sciences Inc. is based in Vancouver, Canada.

Cardiol Therapeutics stock logo

Cardiol Therapeutics NASDAQ:CRDL

$1.52 +0.13 (+9.06%)
Closing price 07/3/2025 03:51 PM Eastern
Extended Trading
$1.46 -0.06 (-3.96%)
As of 07/3/2025 04:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

Cesca Therapeutics stock logo

Cesca Therapeutics NASDAQ:KOOL

Cesca Therapeutics Inc. develops, commercializes, and markets a range of automated technologies and products for cell-based therapeutics in the United States, China, rest of Asia, Europe, and internationally. The company develops automated blood and bone marrow processing systems that enable the separation, processing, and preservation of cell and tissue therapy products. It offers AutoXpress System, a proprietary automated device and companion sterile disposable for concentrating hematopoietic stem cells from cord blood; Point-of-CareXpress System, a proprietary automated device and companion sterile disposable for the isolation and concentration of hematopoietic stem cells from bone marrow; CAR-TXpress System, a suite of multi-component automated system that allows the automated manufacturing, expansion, and storage of cellular therapies for immuno-oncology; BioArchive System, an automated cryogenic device for single-cassette based cryo-storage of biological license applications products; and manual bag sets for use in the processing and cryogenic storage of cord blood. The company is also developing autologous stem cell-based therapies that address medical needs for applications in the vascular, cardiology, and orthopedic markets. In addition, it provides cell manufacturing and banking services. The company was formerly known as ThermoGenesis Corp. and changed its name to Cesca Therapeutics Inc. in February 2014. Cesca Therapeutics Inc. was founded in 1986 and is headquartered in Rancho Cordova, California. Cesca Therapeutics Inc. is a subsidiary of Boyalife (Hong Kong) Limited.

ThermoGenesis stock logo

ThermoGenesis NASDAQ:THMO

ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for cell-banking, cell-processing, and cell-based therapeutics in the United States, China, the United Arab Emirates, Vietnam, and internationally. The company provides medical device products for automated cell processing. Its clinical bio-banking applications include AXP II Automated Cell Separation System, an automated fully closed cell separation system for isolating stem and progenitor cells from umbilical cord blood; and BioArchive Automated Cryopreservation System, an automated, robotic, liquid nitrogen controlled-rate-freezing and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications. The company's point-of-care applications include XP Point-of-Care System, an automated, fully closed, sterile system that allows for the rapid and automated processing of autologous peripheral blood or bone marrow aspirate derived stem cells at the point-of-care, such as surgical centers or clinics; and PXP-1000 System, an automated, fully closed system that provides fast, reproducible separation of multiple cellular components from blood with minimal red blood cell contamination. Its cell processing products comprise X-Series products for general laboratory use, such as X-Lab for cell isolation, X-Wash System for cell washing and reformulation, and X-Mini for high efficiency small scale cell purification. The company also provides contract development and manufacturing services for cell and cell-based gene therapies. It markets and sells its medical device products through independent distributors, as well as direct to end-user customers. The company was formerly known as Cesca Therapeutics Inc. and changed its name to ThermoGenesis Holdings, Inc. in November 2019. ThermoGenesis Holdings, Inc. was incorporated in 1986 and is headquartered in Rancho Cordova, California.